000157614 001__ 157614
000157614 005__ 20240229133507.0
000157614 0247_ $$2doi$$a10.2967/jnumed.120.246363
000157614 0247_ $$2pmid$$apmid:32817141
000157614 0247_ $$2ISSN$$a0022-3123
000157614 0247_ $$2ISSN$$a0097-9058
000157614 0247_ $$2ISSN$$a0161-5505
000157614 0247_ $$2ISSN$$a1535-5667
000157614 0247_ $$2ISSN$$a2159-662X
000157614 0247_ $$2altmetric$$aaltmetric:88650022
000157614 037__ $$aDKFZ-2020-01711
000157614 041__ $$aeng
000157614 082__ $$a610
000157614 1001_ $$aSprute, Katharina$$b0
000157614 245__ $$aDiagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
000157614 260__ $$aNew York, NY$$bSoc.$$c2021
000157614 3367_ $$2DRIVER$$aarticle
000157614 3367_ $$2DataCite$$aOutput Types/Journal article
000157614 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611560927_13973
000157614 3367_ $$2BibTeX$$aARTICLE
000157614 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157614 3367_ $$00$$2EndNote$$aJournal Article
000157614 500__ $$a2021 Feb;62(2):208-213
000157614 520__ $$aPurpose: Prostate specific membrane antigen (PSMA) -ligand PET/CT is performed in patients with prostate cancer to stage the disease initially or to identify sites of recurrence after definitive therapy. 18F-PSMA-1007 is a promising PSMA-PET tracer based on clinical results, but detailed histologic confirmation has been lacking. Experimental Design: 96 patients with prostate cancer received a 18F-PSMA-1007-PET/CT followed by either radical prostatectomy with lymphadenectomy or salvage lymphadenectomy. The histological findings of PSMA-PET-positive nodes were analysed retrospectively. A lesion and a patient-based analysis was performed comparing 1) all positive and 2) only lesions with a size larger than 3 mm in histopathology. Results: 90.6% of the patients received 18F-PSMA-1007-PET/CT for staging before the primary treatment, while 9.4 % of the cohort underwent imaging for biochemical recurrence. In 34.4% of the cohort positive lymph nodes were present in imaging. A total of 1746 lymph nodes were dissected in 96 patients. 18F-PSMA-1007-PET had a lesion-based sensitivity of 81.7% a specificity of 99.6%, a positive predictive value (PPV) of 92.4%, a negative predictive value (NPV) of 98.9% for detecting positive lymph nodes larger than 3 mm. In the analysis of all malignant nodes regardless the size the overall sensitivity, specificity, PPV, and NPV on lesion-based analysis was 71.2%, 99.5%, 91.3%, and 97.9%, respectively. The patient-based analysis showed a sensitivity of 85.9% and a specificity of 99.5% for lymph nodes >3 mm. Conclusion:18F-PSMA-1007-PET/CT reliably detects malignant lymph nodes and has an exceptional specificity of >99% for nodal metastases.
000157614 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000157614 588__ $$aDataset connected to CrossRef, PubMed,
000157614 7001_ $$aKramer, Vasko$$b1
000157614 7001_ $$aKoerber, Stefan$$b2
000157614 7001_ $$aMeneses, Manuel$$b3
000157614 7001_ $$aFernandez, Rene$$b4
000157614 7001_ $$aSoza-Ried, Cristian$$b5
000157614 7001_ $$aEiber, Mathias$$b6
000157614 7001_ $$aWeber, Wolfgang$$b7
000157614 7001_ $$aRauscher, Isabel$$b8
000157614 7001_ $$aRahbar, Kambiz$$b9
000157614 7001_ $$aSchaefers, Martin$$b10
000157614 7001_ $$aWatabe, Tadashi$$b11
000157614 7001_ $$aUemura, Motohide$$b12
000157614 7001_ $$aNaka, Sadahiro$$b13
000157614 7001_ $$aNonomura, Norio$$b14
000157614 7001_ $$aHatazawa, Jun$$b15
000157614 7001_ $$aSchwab, Constantin$$b16
000157614 7001_ $$aSchütz, Viktoria$$b17
000157614 7001_ $$aHohenfellner, Markus$$b18
000157614 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b19$$udkfz
000157614 7001_ $$aDebus, Juergen$$b20
000157614 7001_ $$aKratochwil, Clemens$$b21
000157614 7001_ $$aAmaral, Horacio$$b22
000157614 7001_ $$aChoyke, Peter L$$b23
000157614 7001_ $$aHaberkorn, Uwe$$b24
000157614 7001_ $$aSandoval, Camilo$$b25
000157614 7001_ $$aGiesel, Frederik L$$b26
000157614 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.120.246363$$gp. jnumed.120.246363 -$$n2$$p208-213$$tJournal of nuclear medicine$$v62$$x2159-662X$$y2021
000157614 909CO $$ooai:inrepo02.dkfz.de:157614$$pVDB
000157614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000157614 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157614 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000157614 9141_ $$y2021
000157614 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2018$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-18
000157614 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2018$$d2020-01-18
000157614 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000157614 980__ $$ajournal
000157614 980__ $$aVDB
000157614 980__ $$aI:(DE-He78)C060-20160331
000157614 980__ $$aUNRESTRICTED